 Purpura, Thrombotic Thrombocytopenic
"Purpura, Thrombotic Thrombocytopenic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE.
| Descriptor ID |
D011697
|
| MeSH Number(s) |
C15.378.100.802.687.680 C15.378.140.855.925.750.680 C15.378.925.850 C23.550.414.950.687.680 C23.888.885.687.687.680
|
| Concept/Terms |
Purpura, Thrombotic Thrombocytopenic- Purpura, Thrombotic Thrombocytopenic
- Thrombocytopenic Purpura, Thrombotic
- Moschkowitz Disease
- Disease, Moschkowitz
- Thrombotic Thrombocytopenic Purpura
- Moschcowitz Disease
- Disease, Moschcowitz
- Purpura, Thrombotic Thrombopenic
- Thrombopenic Purpura, Thrombotic
- Thrombotic Thrombopenic Purpura
Congenital Thrombotic Thrombocytopenic Purpura- Congenital Thrombotic Thrombocytopenic Purpura
- Schulman-Upshaw Syndrome
- Schulman Upshaw Syndrome
- Syndrome, Schulman-Upshaw
- Upshaw-Schulman Syndrome
- Syndrome, Upshaw-Schulman
- Upshaw Schulman Syndrome
- Thrombotic Thrombocytopenic Purpura, Congenital
- Upshaw Factor, Deficiency of
- Microangiopathic Hemolytic Anemia, Congenital
- Thrombotic Microangiopathy, Familial
- Familial Thrombotic Microangiopathy
- Microangiopathy, Familial Thrombotic
|
Below are MeSH descriptors whose meaning is more general than "Purpura, Thrombotic Thrombocytopenic".
- Diseases [C]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Blood Coagulation Disorders [C15.378.100]
- Purpura [C15.378.100.802]
- Purpura, Thrombocytopenic [C15.378.100.802.687]
- Purpura, Thrombotic Thrombocytopenic [C15.378.100.802.687.680]
- Blood Platelet Disorders [C15.378.140]
- Thrombocytopenia [C15.378.140.855]
- Thrombotic Microangiopathies [C15.378.140.855.925]
- Purpura, Thrombocytopenic [C15.378.140.855.925.750]
- Purpura, Thrombotic Thrombocytopenic [C15.378.140.855.925.750.680]
- Thrombophilia [C15.378.925]
- Purpura, Thrombotic Thrombocytopenic [C15.378.925.850]
- Pathological Conditions, Signs and Symptoms [C23]
- Pathologic Processes [C23.550]
- Hemorrhage [C23.550.414]
- Purpura [C23.550.414.950]
- Purpura, Thrombocytopenic [C23.550.414.950.687]
- Purpura, Thrombotic Thrombocytopenic [C23.550.414.950.687.680]
- Signs and Symptoms [C23.888]
- Skin Manifestations [C23.888.885]
- Purpura [C23.888.885.687]
- Purpura, Thrombocytopenic [C23.888.885.687.687]
- Purpura, Thrombotic Thrombocytopenic [C23.888.885.687.687.680]
Below are MeSH descriptors whose meaning is more specific than "Purpura, Thrombotic Thrombocytopenic".
This graph shows the total number of publications written about "Purpura, Thrombotic Thrombocytopenic" by people in this website by year, and whether "Purpura, Thrombotic Thrombocytopenic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2016 | 2 | 0 | 2 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 2 | 2 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2024 | 0 | 1 | 1 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Purpura, Thrombotic Thrombocytopenic" by people in Profiles.
-
Jacobs JW, Adkins BD, Booth GS, Stanek CG, Allen ES, Grossman BJ, Stephens LD, Crowe EP, Daou L, Marques MB, Siniard RC, Wallace LR, Yamada C, Duque MA, Wu Y, Aljuboori O, Harrington TJ, Byrnes DM, Eichbaum Q, Figueroa Villalba CA, Juskewitch JE, Klapper E, Perez-Alvarez I, Klein MS, Aldarweesh F, Alkhateb R, Parsons MG, Schlueter AJ, Tormey CA, Wheeler AP, Powers AA, Webb CB, Yates SG, Bloch EM, Raval JS. A Descriptive 5-Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021. J Clin Apher. 2025 Apr; 40(2):e70017.
-
Jacobs JW, Stanek CG, Booth GS, Symeonidis A, Shih AW, Allen ES, Gavriilaki E, Grossman BJ, Pavenski K, Moorehead A, Peyvandi F, Agosti P, Mancini I, Stephens LD, Raval JS, Mingot-Castellano ME, Crowe EP, Daou L, Pai M, Arnold DM, Marques MB, Henrie R, Smith TW, Sreenivasan G, Siniard RC, Wallace LR, Yamada C, Duque MA, Wu Y, Harrington TJ, Byrnes DM, Bitsani A, Davis AK, Robinson DH, Eichbaum Q, Figueroa Villalba CA, Juskewitch JE, Kaiafa G, Kapsali E, Klapper E, Perez-Alvarez I, Klein MS, Kotsiou N, Lalayanni C, Mandala E, Aldarweesh F, Alkhateb R, Fortuny L, Mellios Z, Papalexandri A, Parsons MG, Schlueter AJ, Tormey CA, Wellard C, Wood EM, Jia S, Wheeler AP, Powers AA, Webb CB, Yates SG, Bouzid R, Coppo P, Bloch EM, Adkins BD. The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi-center analysis of 719 disease episodes. Am J Hematol. 2024 Nov; 99(11):2063-2074.
-
Abou-Ismail MY, Zhang C, Presson AP, Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sridharan M, Go RS, McCrae KR, Upreti HV, Gangaraju R, Kocher NK, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa M, Lim MY. A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry. Blood Adv. 2024 02 13; 8(3):620-623.
-
Metjian A. iTTP: more long-term consequences. Blood. 2023 01 19; 141(3):216-217.
-
Scully M, de la Rubia J, Pavenski K, Metjian A, Kn?bl P, Peyvandi F, Cataland S, Coppo P, Kremer Hovinga JA, Minkue Mi Edou J, De Passos Sousa R, Callewaert F, Gunawardena S, Lin J. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. J Thromb Haemost. 2022 12; 20(12):2810-2822.
-
Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Liu A, Lim MY, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson A, Davis E, Evans MD, Mazepa MA. Race, rituximab, and relapse in TTP. Blood. 2022 09 22; 140(12):1335-1344.
-
Costello A, Pandita A, Devitt J. Case Report: Thrombotic Thrombocytopenia after COVID-19 Janssen Vaccination. Am Fam Physician. 2021 06 01; 103(11):646-647.
-
Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021 04 27; 5(8):2137-2141.
-
Baek JH, Shin HKH, Koo SM, Gao Y, Qu H, Feng X, Xu X, Pinto J, Katneni U, Kimchi-Sarfaty C, Buehler PW. Polyethylene Oxide Molecular Size Determines the Severity of Atypical Thrombotic Microangiopathy in a Guinea Pig Model of Acute Intravenous Exposure. Toxicol Sci. 2020 09 01; 177(1):235-247.
-
Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020 02; 18(2):479-484.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|